The Hemoglobinopathies Market size is estimated to reach $14.3 billion by 2027 and it is poised to grow at a CAGR of 10.2% over the forecast period of 2022-2027. Hemoglobinopathies is a hereditary and genetic disorder that affects the structure, function or production of the key hemoglobin. Examples of hemoglobinopathies or types of hemoglobinopathies are thalassemia of alpha and beta class, sickle cell disease and hemoglobin E and C disease amongst others. Hemoglobinopathies can be or cannot be dangerous based on criticality. Hemoglobinopathies screening is a critical aspect in understanding the criticality of the disease/condition. Hemoglobinopathies cannot be cured permanently. However, it can be treated as per the stage and medical requirements by using various therapeutics. Governments across the globe are trying to understand the importance of Hemoglobinopathy fa results or fetal hemoglobin to eradicate the condition from new-born. 

Hemoglobinopathies Market Drivers

Massive Growth in the Cases of Hemoglobinopathies In 3rd World and Low-Income Nations:

As per a report by the American Society of Hematology - nearly 95% of children born in low- and middle-income countries are born with thalassemia. The prevalence of such conditions has spread through the developed nations owing to excessive migration in the timelines. Critically, race and ethnicity of the population play a key role in understanding the incidence and prevalence. For example, 1 in every 365 African-American births has SCD, while Hispanic-American birth with SCDs is 1 in every 16,300 births.

The Growing Awareness Regarding the Control of such Conditions/Diseases:

As per WHO, in all countries of the World, plans of action to manage and control Hb disorders are needed, covering community awareness and education, training of health care professionals and infrastructure development to strengthen diagnostic and transfusion services. WHO is playing a critical role in subsiding the incidence within South-East Asia where the genetic prevalence in 2020 for thalassemia stood at 2.5-15%.

For More Queries About "Hemoglobinopathies Market" @

Partnerships and Acquisitions

In September 2022, Azerbaijan Thalassemia Center and BGI China entered into a partnership to improve thalassemia screening in Azerbaijan. Such a change would be adapted with the help of genetic technology. In January 2022, Novo Nordisk entered into a definitive agreement to acquire Forma Therapeutics for nearly $1.1 billion via cash transaction. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and rare blood disorders.

The Major Players In The Market

The major players in the Hemoglobinopathies Market include Sysmex Corp, Pfizer, Siemens, PerkinElmer, Nexcelon Bioscience LLC, Novo Nordisk, BGI (Huada Biotechnology), Bio-Rad Labs, Mindray Medical International and Danaher Corporation.

The development of novel curative technologies, such as CRISPR/Cas9 and hematopoietic stem cell transplantation, coupled with a promising pipeline, is expected to propel market growth. An increase in investment and funding for the development of novel therapies to treat hemoglobinopathies would further boost the market growth over the forecast period of 2022-2027.

To request for a quote, provide your details in the below link:

Media Contact:
Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.